Stephen James - Swedish Orphan Insider

Swedish Orphan Biovitrum AB -- USA Stock  

USD 14.72  0.0005  0.0034%

Vice President Head of Drug Design and Development

Mr. Stephen James serves as Vice President, Head of Drug Design and Development at Swedish Orphan Biovitrum AB . He was employed by the Company since 2001. He previously held a number of management positions in Research and PreClinical Development in Pharmacia Upjohn, Pharmacia AB and Biovitrum AB. Prior to this, he served as University of Dundee Research Fellow, the United Kingdom. He holds a Doctorate of Philosophy degree in Biochemistry and Cell Biology from the University of Leeds, and a BS degree in Biochemistry and Microbiology from the University of St. Andrews.
Age: 49    Ph.D    
46 86 97 20 00  http://www.sobi.com

Management Efficiency

The company has return on total asset (ROA) of 5.92 % which means that it generated profit of $5.92 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 11.34 % meaning that it generated $11.34 on every $100 dollars invested by stockholders.
The company has accumulated 60.4 M in total debt with debt to equity ratio (D/E) of 8.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum AB has Current Ratio of 1.69 which is within standard range for the sector.

Similar Executives

Showing few of many executives

PRESIDENT Since

Jose PazMetro Pacific Investments Corpo
2007
Lijun ZhaoCHINA LIFE
2016
Melanie BendijoMetro Pacific Investments Corpo
2015
Karim GarciaMetro Pacific Investments Corpo
2015
Armin TulioUyMetro Pacific Investments Corpo
2016
Haifeng XuCHINA LIFE
2015
Reymundo CochangcoMetro Pacific Investments Corpo
2010
Maricris AldoverYsmaelMetro Pacific Investments Corpo
2016
Celso LopezMetro Pacific Investments Corpo
2014
Maida BruceMetro Pacific Investments Corpo
2009
Robin VelascoMetro Pacific Investments Corpo
2009
Ricardo PilaresMetro Pacific Investments Corpo
2015
Ferdinand InacayMetro Pacific Investments Corpo
2010
Santhea SantosMetro Pacific Investments Corpo
2014
Dairen LinCHINA LIFE
2014
Ying ZhouCHINA LIFE
2008
Melody RosarioMetro Pacific Investments Corpo
2009
Loudette ZoiloMetro Pacific Investments Corpo
2012
Jose LaurelMetro Pacific Investments Corpo
2016
Albert PulidoMetro Pacific Investments Corpo
2009
Jianyou XiaoCHINA LIFE
2016

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Swedish Orphan Biovitrum AB to your portfolio

Top Management

Swedish Orphan Biovi Leadership Team
Hans Wigzell, Director, Ph.D
Lennart Johansson, Director, MBA
Annette Clancy, Director
Trista Morrison, President
Kirsti Gjellan, President
Jorgen Winroth, VP
Milan Zdravkovic, President, Ph.D
Hans Schikan, Director
Dennis Pedersen, President
Helena Saxon, Director, MBA
Anders Edvell, Executive, MBA
Geoffrey McDonough, CEO, Ph.D
Lars Dreioee, President, MBA
Alan Raffensperger, COO
Fredrik Berg, Executive
BoGunnar Rosenbrand, Director
Adine Axen, Director
Birgitte Volck, President
MatsOlof Wallin, President
Stefan Fraenkel, President, MBA
Hakan Bjorklund, Chairman, Ph.D
Cecilia Forberg, President
Stephen James, President, Ph.D
Bo Hansen, Chairman, Ph.D
Armin Reininger, President, Ph.D
Catarina Larsson, Director
Wills HughesWilson, President
Guido Oelkers, CEO
Jeffrey Jonas, Director, Ph.D
Matthew Gantz, Director, MBA
Theresa Heggie, Director

Stock Performance

Swedish Orphan Performance Indicators